ACKNOWLEDGMENTS

The Editorial Board of Clinical Science gratefully acknowledges the assistance given by the following referees during the year 1995.

Abernathy, D.
Agardh, E.
Agrotis, A.
Aitkenhead, A.R.
Ali, N.
Anderson, D.
Anderson, S.
Andrews, F.
Angelin, B.
Araki, S.
Archard, L.
Ardawi, M.S.M.
Arieff, A.I.
Armstrong, V.W.
Arnold, J.M.O.
Amqvist, H.
Arslanian, S.
Arthur, J.
Astarie Dequecker, C.
Bailey, R.R.
Baines, A.
Bankir, L.
Banks, R.
Barclay, R.
Baron, A.D.
Barradas, M.A.
Barrett, E.J.
Barton, H.
Bassie, J.E.
Batchelard, H.
Beaudouin-Legros, M.
Beavan, L.
Beckett, G.
Bell, J.
Belpaire, F.
Benjamin, N.
Bennett, A.
Berl, T.
Berne, C.
Besley, G.
Best, J.
Beynon, H.
Bharaj, H.S.
Bhatnagar, D.
Bie, P.
Bishop, J.
Bistrian, B.R.
Black, C.
Blomberg, P.
Bobik, A.

Boer, W.H.
Bolter, C.P.
Bonham, J.
Bolton, C.
Boot-Handford, R.
Boughton-Smith, N.K.
Boulangier, C.
Bowyer, D.E.
Brain, S.D.
Brands, M.
Brasseur, D.
Bray, M.E.
Brodie, D.
Brown, M.A.
Bryer-Ash, M.
Bund, S.
Burdett, D.
Burdon, R.H.
Burgess, A.W.
Burrell, L.M.
Calder, P.C.
Calver, A.
Cameron, N.E.
Campbell, E.
Caprio, S.
Carlson, M.G.
Caro, C.G.
Casadei, B.
Casalaro, A.
Charles, C.
Chau, N.P.
Cherniak, N.
Cherrington, A.
Ch'ing, J.L.C.
Chowienczyk, P.J.
Chung, K.F.
Clapp, J.
Clarke, C.
Clay, V.
Clayton, P.
Cleland, J.
Clement, D.L.
Cline, G.
Cockcroft, J.R.
Cole, A.T.
Collins, A.
Collins, P.
Cooke, J.P.
Crotty, B.

Crouch, M.
Cruickshank, J.K.
Cuspidi, C.
Dantzker, D.
Dart, T.
Davidson, N.
Davies, D.
Davies, M.
Dausse, J.P.
Day, C.P.
De Backer, G.
Deegan, P.C.
de Jong, N.
de Leeuw, P.W.
de Rijke, Y.B.
de Vernejoul, M.C.
Deutz, N.
Dimsdale, J.E.
Dockray, G.J.
Donker, A.J.M.
Donnelly, S.
Dooley, D.
Dornhurst A.
Dowling, D.
Dransfield, I.
Drejer, K.A.
Dryden, S.
Dullaart, R.P.F.
Duret, D.
During, M.
Duthie, G.
Edelman, A.
Edelson, G.
Ec, H.
Elahi, D.
Elia, M.
Emery, P.W.
Emmerich, J.
Enholm, C.
Eriksen, E.F.
Eriksson, U.
Escourrou, P.
Esler, M.D.
Espiner, E.A.
Evans, B.
Fallen, E.
Fearon, K.
Feiz, T.
Feldman, R.
Feray, J.C.
Ferguson, A.

Fernig, D.
Ferrari, A.U.
Ferrari, M.D.
Feuvray, D.
Fitchett, D.
Ford, G.A.
Forster, C.
Forsling, M.
Forte, L.R.
Fosang, A.
Franceschini, G.
Frayn, K.N.
Freedman, D.
Freestone, S.
Frelin, C.
Friedman, P.
Fryburg, D.
Fuller, B.J.
Furst, P.
Garlick, P.
Gaultier, C.
Gefland, R.A.
Gellai, M.
Gibson, P.
Gilchrist, N.L.
Goode, G.K.
Goodlad, R.
Gore, M.
Gosden, C.M.
Goto, K.
Grassi, G.
Green, A.
Green, C.J.
Griffiths, R.
Griffiths, T.M.
Grimble, G.
Grimm, M.
Groop, L.
Grüber-Leobenstein, B.

Haddad, F.
Hales, C.
Hales, J.
Hall, M.J.
Halliday, D.
Hans, G.
Hansen, P.R.
Hanson, U.
Harding, J.J.
Harris, K.

Head, G.A.
Heagerty, A.M.
Helft, G.
Henderson, I.S.
Hill, J.
Hjemdahl, P.
Holder, D.S.
Home, P.D.
Hother Nielsen, O.
Hughes, A.
Hughes, P.
Hughson, R.
Huisman, R.M.
Hulcrantz, R.
Hunter, J.
Ikeda, U.
Ikram, H.
Imai, Tii.
Ind, P.
Iouzaalen, L.
Iredale, J.P.
Jack, C.I.A.
Jackson, M.J.
Jain, B.
Jakeman, P.M.
Janssen, W.M.T.
Jenkinson, S.
Jennings, G.L.
Jensen, M.
Johnson, M.R.
Johnston, P.W.
Johnstone, F.
Jones, D.
Jones, M.
Jover, B.
Julius, S.
Kamen, P.
Kaplan, A.
Khan, F.
Kingsnorth, A.N.
Kingwell, B.
Kinnear, W.
Klein, G.
Knox, A.
Knox, F.
Koomans, H.A.
Kopp, U.
Korner, P.
Kostuk, W.
Krediel, R.Th.
Acknowledgments
AUTHOR INDEX

Abdel-Meguid, E. 187–191
Abdel-Tawab, S. 187–191
Abu-Amsha, M.T. 155–161
Ainley, C. 219–223
Albert, J. 225–231
Allan, P.L. 17–21
Almada, A.L. 113–118
Amadi, A.A. 391–398
Andersen, S.E. 99–106
Armstrong, A.L. 685–690
Aronson, J.K. 725–731
Arthur, J.R. 107–111
Atucha, N.M. 733–738
Baker, G. 51–58
Barbara, L. 219–223
Barden, A. 711–718
Beilin, L.J. 449–458, 711–718
Belch, J.F.F. 17–21
Benn, J. 575–582
Bernard, C. 29–33
Bernardi, L. 35–43
Bianchetti, M.G. 347–351
Binah, O. 233–239
Blakemore, S.J. 591–599
Bongso, A. 248–249
Boulton, R. 503–507
Bourgin, P. 45–50
Bradford, A. 337–345
Bragado, M.J. 365–369, 771
Bragulat, E. 155–161
Bund, S.J. 739–743
Buvry, A. 319–327
Cacciafesta, A.M. 385–389
Cailmail, S. 29–33
Calverley, P.M.A. 513–518
Calvo, J.J. 365–369, 771
Campbell, B.J. 359–364
Canali, C. 275–281
Carter, J. 513–518
Cartouzou, G. 209–212
Carver, J.G. 725–731
Casco, G. 99–106
Cassell, T.B. 509–512
Castleden, C.M. 467–474
Cattell, V. 375–384
Celli, V. 385–389
Cester, N. 719–723
Chadwick, I.G. 617–620
Chan, S.H. 256–258
Chan, S.Y. 250–252
Charles, C.H. 283–291
Chin-Dusting, J. 23–28
Christensen, N.J. 621–626
Chua, T.P. 391–398
Ciopollina, M.R. 703–710
Claassen, J.A.H.R. 483–488
Clague, J.E. 513–518
Clark, M.L. 425–430
Cots, A.J.S. 391–398
Coca, A. 155–161
Colombani, V. 209–212
Colombo, R. 391–398
Compston, J.E. 307–312
Connell, J.M.C. 65–71
Cook, H.T. 375–384
Coupland, C.A.C. 685–690
Cowley, A.J. 415–423
Crawley, J. 51–58
Crijns, F.R.L. 131–139
Critchley, J.A.H. 35–43
Croft, K.D. 449–458, 711–718
Curran, A.K. 337–345
D’Almeida, M. 29–33
Davies, P.S.W. 763–769
Day, J.M.E. 763–769
de Silva, H.A. 725–731
De Chazal, R. 169–175
De La Sierra, A. 155–161
De Leeuw, P.W. 163–168
De Propris, A.M. 385–389
De Rooij, M.J. 431–439
Ding, X.-J. 93–98
Dowling, R.H. 509–512
Drummond, P.D. 73–77
Dudley, F. 23–28
Dunr, E. 703–710
Duthie, G.G. 107–111
Dutto, F. 313–318
Earnest, C.P. 113–118
El-Gamal, N. 627–631
Elliott, H.L. 65–71
Elliott, R.A. 467–474
Ellory, J.C. 353–358
Engelman, J.L. 509–512
Escourrou, P. 45–50
Espiner, E.A. 283–291
Essén, P. 99–106
Eto, T. 293–298
Fagbemi, O.S. 745–754
Farag, M.M. 187–191
Farmer, R.D.T. 87–92
Farzaneh, F. 213–218
Feigel, P. 45–50
Felzen, B. 233–239
Feng, Y.-H. 459–466
Finch, P.M. 73–77
Finnie, I.A. 359–364
Flanagan, G.J. 353–358
Forster, C.D. 425–430
Fortepiani, L.A. 733–738
Fowler, B. 79–86
Frank, S.M. 627–631
Frayn, K.N. 425–430, 679–683
Freestone, S. 177–185
Fricker, G. 79–86
Frossard, N. 319–327
Frostell, C. 225–231
Gafter, U. 519–523
Garbarg, M. 319–327
Garcia, L.J. 365–369, 771
Garcia-Estafi, J. 733–738
Garlick, P.J. 99–106
Gaskin, G. 329–335
Gerolami, A. 209–212
Ghosh, S. 213–218
Gibson, A. 633–638
Gilman, A.G. 527–537
Giner, V. 155–161
Giordano, A. 391–398
Glenville, B. 51–58
Goldman, J.M. 329–335
Author Index

Pearson, M.G. 513–518
Peeters, L.L.H. 163–168
Peheim, E. 347–351
Pereira, S.P. 509–512
Peeters, L.L.H. 163–168
Peters, A.M. 329–335
Peters, T.J. 213–218
Pettrulato, M. 313–318
Petrie, J.R. 65–71
Pickin, D.M. 399–413, 773–774
Piepoli, M. 391–398
Peters, T.J. 213–218
Plusa, S.M. 371–374
Poaty, V. 319–327
Ponikowski, P. 391–398
Posner, B.A. 527–537
Potter, J.F. 59–64
Powers, H. 633–638
Prasad, K. 441–448
Primrose, J.N. 371–374
Proudfoot, J.M. 449–458
Puddey, I.B. 449–458
Qureshi, I.A. 93–98
Rabini, R.A. 719–723
Radda, G.K. 691–702
Rae, C. 353–358
Raja, S.N. 627–631
Ramsay, L.E. 399–413, 617–620, 773–774
Ravel, U. 51–58
Recchi, D. 385–389
Reitsma, W.D. 583–589
Ren, E.C. 256–258
Rennie, M.J. 591–599
Rhodes, J.M. 359–364
Ricci, C. 219–223
Richards, A.M. 3–16, 283–291, 525
Rickhuss, P.K. 591–599
Ritchie, J. 711–718
Rooyackers, O.E. 475–481
Rouleau, A. 319–327
Rovera, L. 313–318
Ryan, J. 23–28
Radek, S.K. 359–364
Samra, J.S. 425–430, 679–683
Samson, R.R. 177–185
San Roman, J.L. 365–369, 771
Sanderson, A.L. 691–702
Sanderson, J.E. 35–43
Savill, J. 329–335
Schibler, A. 347–351
Schwartz, J.-C. 319–327
Scuteri, A. 385–389
Selldén, E. 431–439
Shan, Y.-F. 93–98
Shehata, R. 187–191
Shirley, D.G. 299–305
Shirey, C. 51–58
Silvester, W. 567–573
Silvani, V. 209–212
Simpson, E.J. 425–430
Simpson, R.J. 213–218
Skipworth, S. 73–77
Sladen, G.E. 509–512
Slutter, W.J. 583–589
Smith, A.J. 583–589
Smith, C.C.T. 87–92
Smith, M.A. 763–769
Sönksen, P.H. 575–582
Soupison, T. 29–33
Sredni, B. 519–523
Staffolani, R. 719–723
Stritoni, P. 275–281
Struikjek-Boudier, H.A.J. 131–139
Stubbs, T.A. 415–423
Sugimori, K. 755–761
Summers, L.K.M. 679–683
Swales, J.D. 59–64
Tan, C.C. 258–260
Tavakoli, R. 319–327
Tay, A. 264–266
Taylor, B.A. 359–364
Taylor, D.J. 169–175
Taylor, E.A. 261–264
Tedgui, A. 29–33
Thien, Th. 483–488, 559–565
Thompson, C.H. 691–702
Thorell, A. 99–106
Thornalley, P.J. 575–582
Thorniley, M.S. 51–58
Thornton, H. 59–64
Tjäder, I. 99–106
Toft, J. 621–626
Tomlinson, B. 35–43
Tonkin, A.M. 201–208
Trevisan, M. 703–710
Trevisan, R. 703–710
Truttman, A.C. 347–351
Tsai, J.-F. 601–606
Turney, J.H. 763–769
Tweddel, A. 739–743
Ueda, S. 65–71
Ul Haq, I. 399–413, 773–774
Unwin, R.J. 299–305
Urban-Márquez, A. 155–161
Ussov, W.Yu 329–335
Vaira, D. 219–223
Van Asten, W.N.J.C. 483–488
Van Beck, E. 163–168
Van der Kolk, E. 583–589
Van Es, P.N. 163–168
Van Essen, H. 131–139
Van Goudoever, J. 193–200
Van Haeften, T.W. 583–589
Van Lieshout, J.J. 193–200
Visentini, P. 275–281
Vitale, C. 313–318
Volterrani, M. 391–398
Wagenmakers, A.J.M. 475–481
Wallace, W.A. 685–690
Wällén, N.H. 225–231
Walter, S.J. 299–305
Waters, B.N. 711–718
Watt, P.W. 591–599
Watts, G.F. 567–573
Webster, N. 371–374
Welham, S.J.M. 607–615
Wernerman, J. 99–106
Wesseling, K.H. 193–200
Weston, P.J. 59–64
Whitaker, R.P. 467–474
Widdop, R.E. 147–154
Willekes, C. 163–168
Winears, C.G. 353–358
Wollersheim, H. 483–488, 559–565
Woo, K.S. 35–43
Woodrow, G. 763–769
Wu, P.K. 627–631
Xie, Y. 93–98
Yang, M.C.-M. 601–606
Yang, S. 29–33
Yeo, W.W. 399–413, 617–620, 773–774
Yeung, D.T.K. 35–43
Yeung, L.Y.C. 35–43
Young, R. 307–312
Yu, L.-G. 359–364
Zolesi, G. 719–723
Accidental falls
  oestrogen replacement therapy 685–690
Acetylcholine
  endothelium, Syndrome X 739–743
  nitric oxide, liver cirrhosis 733–738
Action potential
  cardiac muscle, nutritional iron deficiency 233–239
Activation energy
  Na\(^+\), K\(^+\)-ATPase, gestational hypertension 719–723
\(S\)-Adenosylhomocysteine
  metabolism 79–86
\(S\)-Adenosylmethionine
  metabolism 79–86
Adenylate cyclase
  G-proteins, signal transduction 527–537*
Adipose tissue
  microdialysis, catecholamines 425–430
Adipose tissue blood flow
  body mass index 679–683
Adrenaline
  lymphocytes, cyclic AMP 612–626
  \(\alpha\)-Adrenergic receptors
  skin, reflex sympathetic dystrophy 73–77
Adrenergic \(\beta\)-receptors
  lymphocytes, noradrenaline 621–626
  \(\alpha\)-Adrenoceptor antagonist
  thermoregulation 627–631
Adrenomedullin
  G-protein-linked receptors, cyclic AMP 3–16*, 525
  salt, essential hypertension 293–298
Ageing
  lymphocytes, cyclic AMP 621–626
Alcohol
  pancreatitis-associated protein messenger RNA 213–218
Alcoholic cirrhosis
  nitric oxide 23–28
Aliphatic amines
  renal failure, choline transport 353–358
Alkalosis
  hyperventilation, magnesium 347–351

Almitrine
  ventilation, muscle activity 337–345
Ambulatory blood pressure
  left ventricular function, hypertension 275–281
Ambulatory monitoring
  blood pressure, sleep 45–50
Amino acids
  inflammation, cytokines 121–130*
  metabolism, vascular disease 79–86
  renal transplant recipients, cyclosporin A 489–496
  thermogenesis, anaesthesia 431–439
Aminoglycosides
  nephrotoxicity, non-steroidal anti-inflammatory drugs 187–191
Amylase release
  pancreatitis 365–369, 771
Anaesthesia
  amino acids, thermogenesis 431–439
Angina
  cholesterol, lipids 399–413, 773–774
Angiotensin II
  microalbuminuria, non-insulin-dependent diabetes 703–710
Angiotensin type 1 receptor antagonists
  renal vasodilatation, spontaneously hypertensive rats 147–154
Angiotensin-converting enzyme
  genetic polymorphism, bradykinin 617–620
Antioxidant enzyme
  vitamin E, smoking 107–111
Antioxidants
  inflammation, cytokines 121–130*
Antisense oligodeoxynucleotides
  multidrug resistance 93–98
Aorta
  nitric oxide, liver cirrhosis 733–738
Arachidonic acid
  phospholipids, Crohn’s disease 509–512
Arterialization
  insulin sensitivity, forearm blood flow 65–71
Artery
  morphology, syndrome X 739–743
ATP synthesis
Subject Index

- exercise, obesity 691–702
- ATP-sensitive potassium channels
  - potassium channel openers 651–663*
- Atrial natriuretic peptide
  - neutral endopeptidase, ventricular pacing 283–291
  - salt, essential hypertension 293–298
  - potassium channel openers 651–663*
- Autoantigen
  - T-lymphocytes, biliary cirrhosis 551–558
- Autoimmunity
  - T-lymphocytes, biliary cirrhosis 551–558
- Autonomic function
  - baroreflex sensitivity, insulin-dependent diabetes mellitus 59–64
- Autonomic nervous system
  - heart failure, heart rate variability 391–398
  - heart failure, spectral power 35–43
  - Poincaré plot, heart rate variability 201–208
- Autoregulation
  - Na⁺, K⁺-ATPase, ouabain 497–502
- Balance
  - oestrogen replacement therapy 685–690
- Baroreflex sensitivity
  - autonomic function, insulin-dependent diabetes mellitus 59–64
- Bicarbonate-urea method
  - energy expenditure, human immunodeficiency virus infection 241–245
- Biliary cirrhosis
  - autoimmunity, T-lymphocytes 551–558
- Blastocyst transfer
  - human embryos 248–249
- Bleeding time
  - inhaled nitric oxide 225–231
- Blood flow
  - vascular disease, ultrasound 17–21
- Blood pressure
  - ambulatory monitoring, sleep 45–50
  - stroke volume, syncope 193–200
- Blood temperature
  - amino acids, anaesthesia 431–439
- Blood transfusion
  - T-helper 2 cytokines, transforming growth factor 519–523
- Body composition
  - chronic kidney failure 763–769
- Body mass index
  - adipose tissue blood flow 679–683
- Bone mineral density
  - postmenopausal women 307–312
- Bone resorption
  - calcium nephrolithiasis, mineral water 313–318
- Bradykinin
- angiotensin-converting enzyme, genetic polymorphism 617–620
- endothelium, Syndrome X 739–743
- Brain
  - oxidative metabolism, hypertension 539–550
- Brain natriuretic peptide
  - neutral endopeptidase, ventricular pacing 283–291
- Breath-holding time
  - control of breathing, dyspnoea 755–761
- Bronchial hyper-responsiveness
  - lung transplantation, mast cells 319–327
- Bumetanide
  - Na⁺/K⁺/2Cl⁻ co-transport 725–731
- Caerulein
  - pancreatitis, intracellular calcium 365–369, 771
- Caffeic acid
  - lipoprotein oxidation, wine 449–458
- Calcium
  - alkalosis, hyperventilation 347–351
- Calcium antagonist
  - oxidants 459–466
  - urinary bladder 467–474
- Calcium nephrolithiasis
  - mineral water 313–318
- Calcium oxalate
  - urine state of saturation, calcium nephrolithiasis 313–318
- Calcium phosphate
  - urine state of saturation, calcium nephrolithiasis 313–318
- Calf muscle pump function
  - validation, chronic venous insufficiency 483–488
- Cancer
  - eicosanoid production 264–266
  - Helicobacter pylori, serology 219–223
- Capillaroscopy
  - microcirculation 131–139*
- Capsaicin
  - chilli, stomach 252–254
- Carbon dioxide
  - inspiratory effort sensation, sustained loading 513–518
  - recovery 665–677
- Cardiac muscle
  - nutritional iron deficiency 233–239
- Cardiac oxygenation
  - ischaemia, spectrophotometry 51–58
- Catalase
  - diabetes 441–448
- Catecholamines
  - adipose tissue, microdialysis 425–430
- Cell adhesion
  - epidermal stem cells, integrins 141–146*
Cell adhesion molecules
  integrins 639–650*
Cell differentiation
  epidermal stem cells 141–146*
Cell division
  epidermal stem cells 141–146*
Cell proliferation
  epidermal growth factor, gastrointestinal tract 503–507
Cerebral blood supply
  hypertension 539–550
Cerebrovascular disease
  hypertension 539–550
Cervical carcinoma
  DNA testing, papillomavirus 250–252
Chemiluminescence
  oxidants, calcium antagonist 459–466
Chemoreceptors
  heart failure, heart rate variability 391–398
Chilli
  capsaicin, stomach 252–254
Cholecystokinin 8
  intracellular calcium, pancreatitis 365–369, 771
Cholesterol
  coronary heart disease, lipids 399–413, 773–774
Cholesterol metabolism
  creatine supplementation 113–118
Choline transport
  renal failure, haemodialysis 353–358
Chronic kidney failure
  body composition 763–769
Chronic venous insufficiency
  calf muscle pump function, validation 483–488
Cirrhosis
  tumour necrosis factor-α, pentoxifylline 29–33
Clinical research
  progress in Singapore 247–266
Colonic mucin
  corticosteroids, nicotine 359–364
Contractile response
  portal hypertension, octreotide 601–606
Contractility
  cardiac muscle, nutritional iron deficiency 233–239
Control of breathing
  breath-holding time, dyspnoea 755–761
Coronary heart disease
  cholesterol, lipids 399–413, 773–774
Coronary risk
  lipids 399–413, 773–774
Corticosteroids
  mucin, colon 359–364
Creatine supplementation
  lipid metabolism 113–118
Crohn’s disease
  fatty acids, phospholipids 509–512
Cromakalim
  therapeutic targets 651–663*
CV-11974
  renal vasodilatation, spontaneously hypertensive rats 147–154
Cyclic AMP
  G-protein-linked receptors, adrenomedullin 3–16*, 525
  G-proteins, signal transduction 527–537*
  lymphocytes, noradrenaline 621–626
Cyclic GMP
  inhaled nitric oxide 225–231
  neutral endopeptidase, ventricular pacing 283–291
Cyclosporin A
  renal transplant recipients 489–496
Cytochrome aa3
  ischaemia, spectrophotometry 51–58
Cytochrome c oxidase
  muscle wasting, zymosan 475–481
Cytokine
  pentoxifylline, cirrhosis 29–33
Cytokines
  nutrients, inflammation 121–130*
Densitometry
  chronic kidney failure 763–769
Dermis
  ω-adrenergic receptors, reflex sympathetic dystrophy 73–77
Diabetes
  endothelium, dyslipidaemia 567–573
  microcirculation 131–139*
  oxidative stress 441–448
  oxidative stress, glyoxylase 575–582
Diabetes mellitus
  baroreflex sensitivity, autonomic function 59–64
Diabetic foot
  skin microcirculation, neuropathy 559–565
Diaphragm
  almitrine, electromyography 337–345
Diclofenac sodium
  nephrotoxicity, gentamicin 187–191
DNA testing
  papillomavirus, cervical carcinoma 250–252
Dopamine
  5-hydroxytryptamine, renal sodium excretion 177–185
  renal transplant recipients, cyclosporin A 489–496
Dyslipidaemia
  diabetes, endothelium 567–573
Dyspnoea
control of breathing, breath-holding time 755–761

Echocardiography
  left ventricular function, hypertension 275–281

EEG arousal
  blood pressure, sleep 45–50

Eicosanoid production
  hypertension, cancer 264–266

Electromyography
  muscle activity, almitrine 337–345

Embryos
  blastocyst transfer, stem cell production 248–249

Endothelin
  salt, essential hypertension 293–298

Endothelin peptides
  human kidney 267–273*

Endothelin receptors
  human kidney 267–273*

Endothelium
  diabetes, dyslipidaemia 567–573
  phenylephrine, liver cirrhosis 733–738
  Syndrome X 739–743

Energy expenditure
  bicarbonate-urea method, human immunodeficiency virus infection 241–245

Epidermal growth factor
  cell proliferation, gastrointestinal tract 503–507

Epidermal stem cells
  cell adhesion, integrins 141–146*

Epidermis
  α-adrenergic receptors, reflex sympathetic dystrophy 73–77

Epilepsy
  genetic analysis 264–266

Erythropoietin dysregulation
  renal failure 258–260

Essential hypertension
  salt, adrenomedullin 293–298

Exercise
  ATP synthesis, obesity 691–702
  EXP 3174
    renal vasodilatation, spontaneously hypertensive rats 147–154

Familial hypokalaemic periodic paralysis
  sodium pump 261–264

Fatiguability
  cytochrome c oxidase, zymosan 475–481

Fatigue
  inspiratory effort sensation, CO₂ responsiveness 513–518

Fats
  inflammation, cytokines 121–130*

Fatty acids
  phospholipids, Crohn’s disease 509–512

Fetal programming
  maternal nutrition, hypertension 607–615

Fibroblasts
  intracellular pH, free cytosolic calcium 703–710

Flooding dose
  muscle wasting, zymosan 475–481

Fluidity
  Na⁺, K⁺-ATPase, gestational hypertension 719–723

Fluoxetine
  5-hydroxytryptamine, platelet aggregation 87–92

Forearm blood flow
  arterialization 65–71
  menstrual cycle 163–168

Free cytosolic calcium
  microalbuminuria, non-insulin-dependent diabetes 703–710

Furosemide
  sodium depletion 299–305

Gallbladder
  sodium/hydrogen exchanger, sodium absorption 209–212

Gastrointestinal tract
  cell proliferation, epidermal growth factor 503–507

Gene expression
  pancreatitis-associated protein, mouse intestine 213–218

Genetic analysis
  research in Singapore 264–266

Genetic polymorphism
  angiotensin-converting enzyme, bradykinin 617–620

Geniohyoid
  almitrine, electromyography 337–345

Gentamicin
  nephrotoxicity, non-steroidal anti-inflammatory drugs 187–191

Gestational age
  renin, kidney 169–175

Gestational hypertension
  Na⁺, K⁺-ATPase 719–723

Glomerular filtration rate
  renal transplant recipients, cyclosporin A 489–496

Glomerulonephritis
  IgA nephropathy 258–260

Glucocorticoids
  fetal programming, hypertension 607–615

Glucose transport
  sarcolemma, insulin 591–599
Gludopa
renal metabolism 177–185
γ-L-Glutamyl-5-hydroxy-L-tryptophan
renal metabolism 177–185
Glutathione
antioxidants, cytokines 121–130*
Glutathione peroxidase
diabetes 441–448
Glycogenolysis
exercise, obesity 691–702
Glyoxal
diabetes, oxidative stress 575–582
Glyoxylase
diabetes, oxidative stress 575–582
G-protein-linked receptors
adrenomedullin, cyclic AMP 3–16*, 525
G-proteins
signal transduction, adenylyl cyclase 527–537*
Granulocyte activation
inflammatory disease 329–335
Granulocyte pool
111In–59Fe-labeled granulocytes, inflammatory
disease 329–335
Grape juice
phenolic compounds, lipoprotein oxidation 449–458
Growth hormone
male infertility 254–256
Haemodialysis
blood transfusion 519–523
renal failure, choline transport 353–358
Haemodynamics
ischaemia, spectrophotometry 51–58
meal ingestion, insulin 415–423
neutral endopeptidase, ventricular pacing 283–291
pentoxifylline, cirrhosis 29–33
Heart failure
adrenomedullin 3–16*, 525
autonomic nervous system, spectral power 35–43
heart rate variability, autonomic nervous system 391–398
Heart rate
blood pressure, sleep 45–50
Heart rate variability
autonomic nervous system, spectral power 35–43
heart failure, autonomic nervous system 391–398
Poincaré plot, parasympathetic nervous system 201–208
Helicobacter pylori
serology, cancer 219–223
High-performance liquid chromatography
non-transferrin-bound iron, preterm babies 633–638
Hip
bone-mineral density, postmenopausal women 307–312
Homocysteine
metabolism 79–86
Hormone replacement therapy
bone mineral density, postmenopausal women 307–312
Human immunodeficiency virus infection
energy expenditure, bicarbonate-urea method 241–245
Human leucocyte antigens
nasopharyngeal carcinoma 256–258
5-Hydroxytryptamine
dopamine, renal sodium excretion 177–185
platelet aggregation, fluoxetine 87–92
Hyperglycaemia
insulin release, muscle strength 583–589
Hyperinsulinaemic euglycaemic clamp
insulin sensitivity, arteriolarization 65–71
Hypertension
adrenomedullin 3–16*, 525
contractile response, octreotide 601–606
eicosanoid production 264–266
fetal programming, maternal nutrition 607–615
left ventricular function,
echocardiography 275–281
microcirculation 131–139*
Na+, K+-ATPase, ouabain 497–502
oxidative metabolism, brain 539–550
renin, gestational age 169–175
salt, adrenomedullin 293–298
salt sensitivity 155–161
Hyperventilation
alkalosis, magnesium 347–351
Hypokalaemic periodic paralysis
insulin release 583–589
sodium pump 261–264
Hypometabolism
amino acids, anaesthesia 431–439
Hypotension
stroke volume, syncope 193–200
Hypothermia
x-adrenoceptor antagonist 627–631
amino acids, anaesthesia 431–439
Hypothermic preservation
rat heart, protein kinase C inhibitors 745–754
Hypoxia
pancreatitis-associated protein
messenger RNA 213–218
Ibuprofen
nephrotoxicity, gentamicin 187–191
IgA nephropathy
primary glomerulonephritis 258–260
Immune complex disease
  inflammation mediators, nitric oxide 375–384*
Immunity
  nitric oxide 375–384*
Immunostaining
  mast cells, lung transplantation 319–327
  \textsuperscript{111}In-\textsuperscript{99m}Tc-labelled granulocytes
  lung granulocyte pool, inflammatory disease 329–335
Infertility
  growth hormone 254–256
Inflammation
  nutrients, cytokines 121–130*
  nitric oxide, immune complex disease 375–384*
Inflammatory disease
  granulocyte activation, lung granulocyte pool 329–335
  inhaled nitric oxide
Innervation
  lung transplantation 319–327
Inspiratory effort sensation
  CO\textsubscript{2} responsiveness, sustained loading 513–518
Insulin
  adipose tissue blood flow 679–683
  glucose transport, sarcolemma 591–599
  microalbuminuria, non-insulin-dependent diabetes 703–710
  regional haemodynamics, meal ingestion 415–423
Insulin release
  hypokalaemic periodic paralysis 583–589
Insulin sensitivity
  arterialization 65–71
  insulin-dependent diabetes mellitus
    baroreflex sensitivity, autonomic function 59–64
Integrins
  cell adhesion, epidermal stem cells 141–146*
  cell adhesion molecules 639–650*
Interleukin
  blood transfusion 519–523
  nutrients, inflammation 121–130*
Intracellular calcium
  pancreatitis 365–369, 771
Intracellular pH
  microalbuminuria, non-insulin-dependent diabetes 703–710
  intravenous nutrition
    epidermal growth factor 503–507
Intravital microscopy
  microcirculation 131–139*
Inulin clearance
  menstrual cycle 163–168
Iron deficiency
  pancreatitis-associated protein messenger RNA 213–218
Iron overload
  pancreatitis-associated protein messenger RNA 213–218
Ischaemia
  cardiac oxygenation, spectrophotometry 51–58
  oxidants, calcium antagonist 459–466
Is-o-electric focusing
  serology, cancer 219–223
Isoprostan e
  lipid peroxidation, pregnancy 711–718
Keratinocytes
  epidermal stem cells 141–146*
Kidney
  endothelins 267–273*
  fetal programming, hypertension 607–615
  renin, gestational age 169–175
Labelled carbon dioxide
  recovery 665–77
Left ventricular function
  echocardiography, hypertension 275–281
Lipid
  neutrophils, sepsis 371–374
Lipid metabolism
  creatinine supplementation 113–118
  lipoprotein oxidation
    carbon dioxide 665–677
Liver
  autoimmunity, T-lymphocytes 551–558
  cirrhosis
    phenylephrine, nitric oxide 733–738
  loop of Henle
    sodium depletion, frusemide 299–305
  loss of label
    carbon dioxide 665–677
Lung granulocyte pool
  \textsuperscript{111}In-\textsuperscript{99m}Tc-labelled granulocytes, inflammatory disease 329–335
Lung transplantation
  mast cells, bronchial hyper-responsiveness 319–327
Lymphocytes
  cyclic AMP, noradrenaline 621–626
  protein synthesis, stable isotope 99–106
Magnesium
alkalosis, hyperventilation 347–351
Magnetic resonance spectroscopy
ATP synthesis 691–702
Male infertility
growth hormone 254–256
Mast cells
lung transplantation, bronchial
hyper-responsiveness 319–327
Maternal nutrition
fetal programming, hypertension 607–615
Meal ingestion
regional haemodynamics, insulin 415–423
Mean arterial pressure
metabolic risk factors, sex 385–389
Membrane
sarcolemma, glucose transport 591–599
Membrane current
fetal programming, hypertension 607–615
Menstrual cycle
sex hormones, vascular relaxation 163–168
Mesenteric artery
contractile response, octreotide 601–606
Messenger RNA
pancreatitism-associated protein, mouse intestine 213–218
Metabolic risk factors
blood pressure, sex 385–389
Metabolism
amino acids, vascular disease 79–86
thermoregulation, α-adrenoceptor antagonist 627–631
Methodology
labelled carbon dioxide, recovery 665–677
Methylglyoxal
diabetes, oxidative stress 575–582
5-Methyltetrahydrofolate
metabolism 79–86
Microalbuminuria
intracellular pH, free cytosolic calcium 703–710
Microcirculation
cardiovascular disease 131–139*
diabetic foot, neuropathy 559–565
Microdialysis
adipose tissue, catecholamines 425–430
Micropuncture
loop of Henle, frusemide 299–305
Mineral water
calcium nephrolithiasis 313–318
Mitocondria
ischaemia, spectrophotometry 51–58
Morphology
artery, Syndrome X 739–743
Mouse intestine
pancreatitism-associated protein, messenger RNA 213–218
Mucin
corticosteroids, nicotine 359–364
Multidrug resistance
antisense oligodeoxynucleotides 93–98
Muscle
eooestrogen replacement therapy 685–690
Muscle metabolism
exercise, obesity 691–702
Muscle strength
hypokalaemic periodic paralysis 583–589
Muscle wasting
cytochrome c oxidase, zymosan 475–481
Myocardial infarction
cholesterol, lipids 399–413, 773–774
Na+/K+/2Cl− co-transport
platelets 725–731
Na+, K+-ATPase
gestational hypertension 719–723
ouabain, hypertension 497–502
Nasopharyngeal carcinoma
human leucocyte antigens 256–258
Natriuresis
adrenomedullin 3–16*, 525
neutral endopeptidase, ventricular pacing 283–291
Natriuretic peptides
neutral endopeptidase, ventricular pacing 283–291
Natural killer cells
cyclic AMP, noradrenaline 621–626
Nephrotoxicity
gentamicin, non-steroidal anti-inflammatory drugs 187–191
Neuropathy
diabetic foot, skin microcirculation 559–565
Neutral endopeptidase
natriuretic peptides, ventricular pacing 283–291
Neutrophils
total parenteral nutrition, sepsis 371–374
Nicotine
mucin, colon 359–364
Nitric oxide
alcoholic cirrhosis 23–28
diabetes, dyslipidaemia 567–573
immunity 375–384*
phenylephrine, liver cirrhosis 733–738
platelet function 225–231
Nitric oxide synthase
immunity 375–384*
Non-insulin-dependent diabetes
intracellular pH, free cytosolic calcium 703–710
Non-steroidal anti-inflammatory drugs
nephrotoxicity, gentamicin 187–191
Non-transferrin-bound iron
high-performance liquid chromatography, preterm babies 633–638
Noradrenaline
lymphocytes, cyclic AMP 621–626
Subject Index

Nutrients
- inflammation, cytokines 121–130*
- Nutritional iron deficiency
  cardiac muscle 233–239

Obesity
- adipose tissue blood flow 679–683
- ATP synthesis, exercise 691–702

Ocetotide
- contractile response, portal
  hypertension 601–606

Oestrogen replacement therapy
- muscle, balance 685–690
- Na+, K+-ATPase, hypertension 497–502

Oxidants
- calcium antagonist 459–466
- Oxidation
  exercise, obesity 691–702
- Oxidative metabolism
  brain, hypertension 539–550
- Oxidative stress
  diabetes 441–448
  diabetes, glyoxylase 575–582
- Oxygen consumption
  oxidants, calcium antagonist 459–466

Pancreatic acinar cells
- intracellular calcium, pancreatitis 365–369, 771

Pancreatitis
- intracellular calcium 365–369, 771
- Pancreatitis-associated protein
  messenger RNA, mouse intestine 213–218

Papillomavirus
- DNA testing, cervical carcinoma 250–252
- Parao-aminohippurate clearance
  menstrual cycle 163–168

Parasympathetic nervous system
- Poincaré plot, heart rate variability 201–208
- Parenteral nutrition
  epidermal growth factor 503–507

Pentoxifylline
- tumour necrosis factor-α, cirrhosis 29–33

Phagocytosis
- oxidants, calcium antagonist 459–466

Phenolic compounds
- lipoprotein oxidation, wine 449–458

Phentolamine
- thermoregulation 627–631

Phenylephrine
- contractile response, octreotide 601–606
- nitric oxide, liver cirrhosis 733–738

Phosphocreatine breakdown
- exercise, obesity 691–702

Phospholipids
- fatty acids, Crohn’s disease 509–512

Physical activity
- bicarbonate-urea method, human
  immunodeficiency virus infection 241–245

Physical fitness
- lymphocytes, cyclic AMP 621–626

Pinacidil
- insulin release, muscle strength 583–589

Platelet aggregation
- 5-hydroxytryptamine, fluoxetine 87–92
- inhaled nitric oxide 225–231

Platelets
- Na+/K+/2Cl⁻ co-transport 725–731

Plethysmography
- calf muscle pump function 483–488
- forearm blood flow, arterialization 65–71
- Poincaré plot
  parasympathetic nervous system, heart rate variability 201–208

Polymerase chain reaction
- renal endothelins 267–273*

Portal hypertension
- contractile response, octreotide 601–606
  pentoxifylline, cirrhosis 29–33

Post-menopause
- oestrogen replacement therapy 685–690

Post-thrombotic syndrome
- calf muscle pump function, validation 483–488

Postmenopausal women
- bone mineral density 307–312

Posture
- spectral power 35–43

Potassium
- alkalosis, hyperventilation 347–351

Potassium channel openers
- therapeutic targets 651–663*

Pre-eclampsia
- lipid peroxidation 711–718

Pregnancy
- lipid peroxidation 711–718

Pressure natriuresis
- Na+, K+-ATPase, ouabain 497–502

Preterm babies
- non-transferrin-bound iron, high-performance liquid chromatography 633–638

Primary prevention
- coronary heart disease 399–413, 773–774

Protease
- mast cells, lung transplantation 319–327

Protein kinase C inhibitors
- rat heart, hypothermic preservation 745–754

Protein synthesis
- lymphocytes, stable isotope 99–106

Pulse pressure
- metabolic risk factors, sex 385–389

Rat heart
- hypothermic preservation, protein kinase C inhibitors 745–754

Recovery
Subject Index

labelled carbon dioxide 665–677
Reflex sympathetic dystrophy
α-adrenergic receptors, skin 73–77
Renal endotoxins
quantitative polymerase chain reaction
analysis 267–273*
Renal failure
choline transport, haemodialysis 353–358
erthropoietin dysregulation 258–260
Renal plasma flow
renal transplant recipients,
cyclosporin A 489–496
Renal sodium excretion
dopamine, 5-hydroxytryptamine 177–185
Renal transplant recipients
amino acids, dopamine 489–496
Renal tubule
sodium depletion, frusemide 299–305
Renal vasodilatation
angiotensin type 1 receptor antagonists,
spontaneously hypertensive rats 147–154
Renin
gestational age, kidney 169–175
Renin–aldosterone axis
salt sensitivity, hypertension 155–161
Resistance arteries
nitric oxide, alcoholic cirrhosis 23–28
Respiratory frequency
spectral power 35–43
Salt
adrenomedullin, essential hypertension 293–298
Salt sensitivity
hypertension 155–161
Sarcolemma
glucose transport, insulin 591–599
Schizophrenia
genetic analysis 264–266
Secondary prevention
coronary heart disease 399–413, 773–774
Sepsis
neutrophils, total parenteral nutrition 371–374
Serology
Helicobacter pylori, cancer 219–223
Sex
metabolic risk factors, blood pressure 385–389
Sex hormones
menstrual cycle, vascular relaxation 163–168
Signal transduction
G-proteins, adenylate cyclase 527–537*
Singapore
genetic studies 264–266
progress in clinical research 247–266
Skeletal muscle blood flow
meal ingestion, insulin 415–423
Skin
α-adrenergic receptors, reflex sympathetic
dystrophy 73–77
Skin fibroblasts
intracellular pH, free cytosolic calcium 703–710
Skin microcirculation
diabetic foot, neuropathy 559–565
menstrual cycle 163–168
Sleep
blood pressure, ambulatory monitoring 45–50
Smoking
antioxidant enzyme, vitamin E 107–111
lymphocytes, cyclic AMP 621–626
Smooth muscle
nitric oxide, alcoholic cirrhosis 23–28
Sodium absorption
gallbladder, sodium/hydrogen
exchanger 209–212
Sodium clearance
renal transplant recipients,
cyclosporin A 489–496
Sodium depletion
frusemide 299–305
Sodium/hydrogen exchanger
gallbladder, sodium absorption 209–212
Sodium pump
hypokalaemic periodic muscle
paralysis 261–264
Spectral power
autonomic nervous system, heart failure 35–43
Spectrophotometry
cardiac oxygenation, ischaemia 51–58
Spermatogenesis
growth factors 254–256
Spine
bone mineral density, postmenopausal
women 307–312
Spiral laminar flow
vascular disease, ultrasound 17–21
Splanchnic oxygen uptake
amino acids, anaesthesia 431–439
Spontaneously hypertensive rats
oxidative metabolism, brain 539–550
renal vasodilatation, angiotensin type 1 receptor
antagonists 147–154
Stable isotope
lymphocytes, protein synthesis 99–106
Stem cell production
human embryos 248–249
Stomach
chilli, capsaicin 252–254
Stroke
cholesterol, lipids 399–413, 773–774
Stroke volume
blood pressure, syncope 193–200
Subcellular fractionation
muscle wasting, zymosan 475–481
Sudden death
baroreflex sensitivity, insulin-dependent diabetes
mellitus 59–64
Superoxide dismutase
diabetes 441–448
Surgery
lymphocytes, protein synthesis 99–106
Sustained loading
  inspiratory effort sensation, CO₂ responsiveness 513–518
Sympathetic nervous system
  blood pressure, sleep 45–50
Syncope
  blood pressure, stroke volume 193–200
Syndrome X
  artery, morphology 739–743
T-cell receptor genes
  nasopharyngeal carcinoma 256–258
T-helper 2 cytokines
blood transfusion 519–523
T-lymphocytes
  autoimmunity, biliary cirrhosis 551–558
Therapeutic targets
  potassium channel openers 651–663*
Thermogenesis
  amino acids, anaesthesia 431–439
Thermoregulation
  α-adrenoceptor antagonist 627–631
Thyroid hormones
  cardiac muscle, nutritional iron deficiency 233–239
Thyrotoxic periodic paralysis
  sodium pump 261–264
Tissue repair
  lung transplantation 319–327
Tolerance
  T-lymphocytes, biliary cirrhosis 551–558
Total body water
  chronic kidney failure 763–769
Total parenteral nutrition
  neutrophils, sepsis 371–374
Transforming growth factor
  blood transfusion 519–523
Triacylglycerol metabolism
  creatine supplementation 113–118
Tryptophan
  Na⁺, K⁺-ATPase, gestational hypertension 719–723
Tubular function
  renal transplant recipients, cyclosporin A 489–496
Tumour necrosis factor
  nutrients, inflammation 121–130*
  pentoxifylline, cirrhosis 29–33
Tumour suppressor gene
  nasopharyngeal carcinoma 256–258
Ultrasound
  blood flow, vascular disease 17–21
Urinary bladder
  calcium antagonist 467–474
Urine state of saturation
  calcium nephrolithiasis, mineral water 313–318
Urogastrone
  cell proliferation, gastrointestinal tract 503–507
Vascular disease
  blood flow, ultrasound 17–21
  metabolism, amino acids 79–86
Vascular relaxation
  sex hormones, menstrual cycle 163–168
Vascular tone
  menstrual cycle 163–168
Vasoconstriction
  thermoregulation, α-adrenoceptor antagonist 627–631
Vasodilatation
  diabetes, dyslipidaemia 567–573
Vasodilator peptides
  adrenomedullin 3–16*, 525
Vasopressin
  contractile response, octreotide 601–606
Veins
  nitric oxide, alcoholic cirrhosis 23–28
Ventricular pacing
  adrenomedullin 3–16*, 525
Vitamin E
  antioxidant enzyme, smoking 107–111
  inflammation, cytokines 121–130*
White-coat hypertension
  left ventricular function, echocardiography 275–281
Wine
  phenolic compounds, lipoprotein oxidation 449–458
X-ray absorptiometry
  chronic kidney failure 763–769
Zymosan
  muscle wasting, cytochrome c oxidase 475–481